See more : Oiles Corporation (6282.T) Income Statement Analysis – Financial Results
Complete financial analysis of Merrimack Pharmaceuticals, Inc. (MACK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Merrimack Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Macauto Industrial Co., Ltd. (9951.TWO) Income Statement Analysis – Financial Results
- Signal Hill Acquisition Corp. (SGHL) Income Statement Analysis – Financial Results
- Cornerstone Community Bancorp (CRSB) Income Statement Analysis – Financial Results
- EDP Corporation (7794.T) Income Statement Analysis – Financial Results
- NCR Corporation (NCR) Income Statement Analysis – Financial Results
Merrimack Pharmaceuticals, Inc. (MACK)
About Merrimack Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 144.27M | 89.26M | 102.76M | 47.79M | 48.92M | 34.22M | 20.31M | 2.15M |
| Cost of Revenue | 0.00 | 445.00K | 0.00 | 0.00 | 2.23M | 0.00 | 0.00 | 6.91M | 46.00K | 0.00 | 0.00 | 0.00 | 100.63M | 58.28M | 37.66M |
| Gross Profit | 0.00 | -445.00K | 0.00 | 0.00 | -2.23M | 0.00 | 0.00 | 137.36M | 89.21M | 102.76M | 47.79M | 48.92M | -66.42M | -37.97M | -35.51M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 95.21% | 99.95% | 100.00% | 100.00% | 100.00% | -194.11% | -187.01% | -1,653.17% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 11.10M | 49.97M | 67.31M | 160.92M | 160.99M | 138.50M | 147.14M | 125.86M | 365.00K | 0.00 | 0.00 |
| General & Administrative | 2.18M | 2.17M | 2.62M | 5.01M | 16.17M | 15.60M | 28.45M | 0.00 | 0.00 | 30.52M | 21.19M | 15.81M | 8.84M | 0.00 | 0.00 |
| Selling & Marketing | 2.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.62M | 0.00 | 0.00 |
| SG&A | 2.18M | 2.17M | 2.62M | 5.01M | 16.17M | 15.60M | 28.45M | 80.73M | 57.60M | 30.52M | 21.19M | 15.81M | 14.45M | 11.38M | 12.18M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -191.00K | 370.00K | -3.23M | -1.43M | -43.38M | -18.22M | -17.30M | -10.15M | 988.00K | 34.16M | 0.00 | 0.00 |
| Operating Expenses | 2.18M | 2.17M | 2.62M | 5.01M | 27.27M | 65.58M | 95.77M | 241.65M | 218.58M | 169.01M | 168.33M | 141.66M | 14.45M | 11.38M | 12.18M |
| Cost & Expenses | 2.18M | 2.17M | 2.62M | 5.01M | 27.27M | 65.58M | 95.77M | 248.56M | 218.63M | 169.01M | 168.33M | 141.66M | 115.08M | 69.66M | 49.84M |
| Interest Income | 868.00K | 188.00K | 20.00K | 50.00K | 777.00K | 1.30M | 895.00K | 276.00K | 99.00K | 114.00K | 166.00K | 184.00K | 56.00K | 74.00K | 81.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 1.53M | 956.00K | 34.65M | 43.65M | 19.23M | 18.23M | 10.94M | 553.00K | 13.00K | 3.73M | 4.91M |
| Depreciation & Amortization | 167.90K | -890.00K | -288.00K | -2.28M | -1.54M | 4.07M | 5.22M | 6.25M | 4.29M | 3.22M | 2.59M | 3.66M | 5.33M | 4.38M | 2.76M |
| EBITDA | -2.18M | -2.62M | -2.76M | -5.15M | -20.26M | -65.58M | -91.08M | -110.14M | -125.28M | -66.26M | -120.54M | -92.74M | -75.49M | -44.90M | -44.85M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -68.22% | -144.94% | -64.48% | -252.25% | -189.58% | -220.63% | -221.13% | -2,088.08% |
| Operating Income | -2.18M | -1.73M | -2.47M | -2.87M | -22.36M | -65.58M | -95.77M | -110.14M | -129.57M | -66.26M | -120.54M | -92.74M | -80.87M | -49.18M | -47.69M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -76.34% | -145.16% | -64.48% | -252.25% | -189.58% | -236.36% | -242.19% | -2,220.11% |
| Total Other Income/Expenses | 1.01M | 188.00K | 20.00K | -141.00K | -381.00K | -2.89M | -22.64M | -43.38M | -18.22M | -17.30M | -10.15M | 1.47M | 1.19M | -983.00K | -4.79M |
| Income Before Tax | -1.17M | -1.54M | -2.45M | -3.01M | -22.74M | -68.46M | -118.40M | -153.52M | -147.79M | -83.56M | -130.69M | -91.75M | -79.68M | -50.16M | -52.48M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -106.41% | -165.57% | -81.32% | -273.48% | -187.56% | -232.87% | -247.03% | -2,442.97% |
| Income Tax Expense | 12.00K | 3.00K | 3.00K | 14.00K | -1.47M | -7.70M | -42.40M | -13.22M | -3.92M | -3.49M | -2.35M | -4.14M | -440.00K | 3.67M | -3.40M |
| Net Income | -1.18M | -1.54M | -2.46M | -3.03M | -21.27M | -40.51M | 472.03M | -151.74M | -147.96M | -83.29M | -130.93M | -91.28M | -79.22M | -50.10M | -49.07M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -105.18% | -165.76% | -81.06% | -273.98% | -186.58% | -231.54% | -246.76% | -2,284.59% |
| EPS | -0.08 | -0.11 | -0.18 | -0.23 | -1.59 | -3.04 | 35.67 | -12.11 | -13.29 | -7.98 | -13.24 | -12.53 | -8.57 | -44.17 | -43.26 |
| EPS Diluted | -0.08 | -0.11 | -0.18 | -0.23 | -1.59 | -3.04 | 35.67 | -12.11 | -13.29 | -7.98 | -13.24 | -12.53 | -8.57 | -44.17 | -43.26 |
| Weighted Avg Shares Out | 14.30M | 13.52M | 13.41M | 13.38M | 13.35M | 13.34M | 13.23M | 12.53M | 11.14M | 10.44M | 9.89M | 7.28M | 9.24M | 1.13M | 1.13M |
| Weighted Avg Shares Out (Dil) | 14.30M | 13.52M | 13.41M | 13.38M | 13.35M | 13.34M | 13.23M | 12.53M | 11.14M | 10.44M | 9.89M | 7.28M | 9.24M | 1.13M | 1.13M |
Merrimack stock rockets 200% after positive trial data on Onivyde pancreatic cancer treatment
Shares of Merrimack Pharmaceuticals Inc. MACK, +224.14% skyrocketed 199.5% toward a 4 1/2-year high in morning trading Wednesday, after the France-based biopharmaceutical company Ipsen IPSEY, +1.39% IPN, +3.85% said overnight that its Onivyde pancreatic cancer treatment met the primary endpoint...
Return Of The Mack: A Deeply Misunderstood Near-Term Readout
MACK has a $225m milestone if its drug Onivyde works in first-line pancreatic cancer (already approved in second-line). The stock has been badly misvalued because the vast majority of pancreatic cancer drugs are targeted therapies that fail in the clinic.
Merrimack Reports Second Quarter 2021 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) (“Merrimack” or the “Company”) today announced its second quarter 2021 financial results for the period ended June 30, 2021. “We are pleased to report continued reductions in our operating expenses as well as positive...
Merrimack Reports Full Year 2020 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2020 Financial Results
Merrimack Reports Second Quarter 2020 Financial Results
Merrimack Reports Second Quarter 2020 Financial Results
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Insider Sells $363,326.04 in Stock
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) insider Gary L. Crocker sold 117,963 shares of Merrimack Pharmaceuticals stock in a transaction that occurred on Wednesday, July 22nd. The shares were sold at an average price of $3.08, for a total transaction of $363,326.04....
Merrimack Reports First Quarter 2020 Financial Results
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced its first quarter 2020 financial results for the period ended March 31, 2020.
US Stock Market Weekly Update March 30- April 3, 2020
For the week ending on April 3, the US stock market declined and all major stock indexes had losses. We had a negative figure for the US non-far payrolls and the weekly US jobless claims, showing the coronavirus' negative impact...
The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 23.) Arcutis Biotherapeutics...
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) Biomerica, Inc. (NASDAQ: BMRA ) Centogene NV (NASDAQ: CNTG ) Gilead Sciences, Inc. (NASDAQ:...
Source: https://incomestatements.info
Category: Stock Reports